Xenon Pharmaceuticals Inc. (XENE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $55.89: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Xenon Pharmaceuticals is a neuroscience-focused clinical-stage company. Lead candidate azetukalner (Kv7 potassium channel opener) is in Phase 3 for focal onset seizures (X-TOLE2 data expected H1 2026), PGTCS (X-ACKT enrolling), MDD, and bipolar depression. The company had net... Read more
Sell if holding. Engine safety override at $55.89: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineazetukalner10-K Item 1A: 'We have no marketed proprietary products and are advancing clinical development through Phase 3 clinical studies for our azetukalner program'
Material Events(8-K, last 90d)
- 2026-04-13Item 5.02LOWXenon amended 2025 Inducement Equity Plan on April 7, 2026 to increase share reserve from 900,000 to 1,175,000 shares. Compensatory plan amendment; no officer departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $55.89: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $52.15. Score 5.2/10, moderate confidence.
Take-profit target: $71.32 (+27.5% upside). Prior stop was $52.15. Stop-loss: $52.15.
Concentration risk — Pipeline: azetukalner; Quality below floor (1.5 < 4.0).
Xenon Pharmaceuticals Inc. trades at a P/E of N/A (forward -11.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
26 analysts cover XENE with a consensus score of 4.4/5. Average price target: $79.
What does Xenon Pharmaceuticals Inc. do?Xenon Pharmaceuticals is a neuroscience-focused clinical-stage company. Lead candidate azetukalner (Kv7 potassium...
Xenon Pharmaceuticals is a neuroscience-focused clinical-stage company. Lead candidate azetukalner (Kv7 potassium channel opener) is in Phase 3 for focal onset seizures (X-TOLE2 data expected H1 2026), PGTCS (X-ACKT enrolling), MDD, and bipolar depression. The company had net losses of $345.9M in 2025 and an accumulated deficit of $1,245.4M.